Overview

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Status:
Completed

Trial end date:
2019-11-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in adults with advanced or metastatic squamous non-small cell lung cancer (NSCLC).

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel
Veliparib